Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/34642
Title: Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys
Authors: Pestana, Jose Osmar Medina [UNIFESP]
Grinyo, J. M.
Vanrenterghem, Y.
Becker, T.
Campistol, J. M.
Florman, S.
Garcia, V. D.
Kamar, N.
Lang, P.
Manfro, R. C.
Massari, P.
Rial, M. D. C.
Schnitzler, M. A.
Vitko, S.
Duan, T.
Block, A.
Harler, M. B.
Durrbach, A.
Universidade Federal de São Paulo (UNIFESP)
Univ Hosp Bellvitge
Univ Hosp Leuven
Hannover Med Sch
Univ Barcelona
Mt Sinai Med Ctr
Hosp Dom Vicente Scherer
CHU Rangueil
Univ Paris Est
Hosp Clin Porto Alegre
Hosp Privado Ctr Med Cordoba
Inst Nefrol
St Louis Univ
Inst Clin & Expt Med
Bristol Myers Squibb Co
Univ Paris 11
Keywords: Belatacept
cyclosporine
extended criteria donor
kidney
renal function
Issue Date: 1-Mar-2012
Publisher: Wiley-Blackwell
Citation: American Journal of Transplantation. Malden: Wiley-Blackwell, v. 12, n. 3, p. 630-639, 2012.
Abstract: Recipients of extended-criteria donor (ECD) kidneys have poorer long-term outcomes compared to standard-criteria donor kidney recipients. We report 3-year outcomes from a randomized, phase III study in recipients of de novo ECD kidneys (n = 543) assigned (1:1:1) to either a more intensive (MI) or less intensive (LI) belatacept regimen, or cyclosporine. Three hundred twenty-three patients completed treatment by year 3. Patient survival with a functioning graft was comparable between groups (80% in MI, 82% in LI, 80% in cyclosporine). Mean calculated GFR (cGFR) was 11 mL/min higher in belatacept-treated versus cyclosporine-treated patients (42.7 in MI, 42.2 in LI, 31.5 mL/min in cyclosporine). More cyclosporine-treated patients (44%) progressed to GFR <30 mL/min (chronic kidney disease [CKD] stage 4/5) than belatacept-treated patients (2730%). Acute rejection rates were similar between groups. Posttransplant lymphoproliferative disorder (PTLD) occurrence was higher in belatacept-treated patients (two in MI, three in LI), most of which occurred during the first 18 months; four additional cases (3 in LI, 1 in cyclosporine) occurred after 3 years. Tuberculosis was reported in two MI, four LI and no cyclosporine patients. in conclusion, at 3 years after transplantation, immunosuppression with belatacept resulted in similar patient survival, graft survival and acute rejection, with better renal function compared with cyclosporine. As previously reported, PTLD and tuberculosis were the principal safety findings associated with belatacept in this study population.
URI: http://repositorio.unifesp.br/handle/11600/34642
ISSN: 1600-6135
Other Identifiers: http://dx.doi.org/10.1111/j.1600-6143.2011.03914.x
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.